Trials / Completed
CompletedNCT06202599
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance:A Multicenter Retrospective Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 124 (actual)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This multicenter retrospective study assessed the efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after several lines of TKIs' resistance.
Detailed description
The short-lived duration of disease control and secondary drug resistance have posed a threat to the effect of TKIs. Fruquintinib is a novel TKI with a high selectivity of VEGFR-1,2,3 without metabolism by liver enzymes and was approved for application in mCRC. Serious drug resistance and the unique characteristics of fruquintinib have prompted us to verify whether this drug can reverse TKIs' resistance at a higher dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fruquintinib | For patients with pulmonary metastasis only, we mostly gave them fruquintinib with 7 mg in adults and 3-5 mg in children (\<10 years) orally per day (5 days on and 2 days off). If patients were extrapulmonary metastasis, we usually used combinations with metronomic chemotherapy (2/3 or 3/5 or even 1/2 of the usual dose) or immunotherapy. |
Timeline
- Start date
- 2021-11-25
- Primary completion
- 2023-08-29
- Completion
- 2023-11-15
- First posted
- 2024-01-11
- Last updated
- 2024-01-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06202599. Inclusion in this directory is not an endorsement.